ARTICLE SUMMARY:
Elixir Medical hopes to raise the bar for percutaneous coronary Intervention (PCI) with its DynamX Coronary Bioadaptor System, an innovative implant that opens and supports a diseased coronary artery without permanently caging the vessel. DynamX recently outperformed a state-of-the-art drug-eluting stent in a randomized, head-to-head comparison.
Elixir Medical has seen its share of ups and downs after nearly two decades of innovating in the interventional cardiology arena. But the company is clearly on an upswing today. It is one of only a handful of competitors still working to restore normal vessel function following percutaneous coronary intervention (PCI). However, unlike the fully bioresorbable scaffolds (BRS) of the past that were developed with this goal in mind but failed to deliver, Elixir’s DynamX Coronary Bioadaptor System is a unique, adaptive device that combines biocompatible metallic elements to support the artery without permanently caging the vessel. By doing so, it addresses one of the major limitations of existing drug-eluting stents (DES), which rigidify the vessel, and it has the potential to lower the risk of stent-related adverse events. Although outperforming the current DES standard of care (SOC) can be a high bar to clear, randomized clinical trial data presented at this year’s EuroPCR conference suggest Elixir’s device may be able to do just that.
